Corcept Therapeutics Incorporated CORT
73.71 USD -0.82 (-1.10%)
At closeNov 12, 2026, 4:00 PM EST
73.71 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
72.23 Day range 75.50
28.66 52-week range 126.38
- YTD
- +111.81%
- 1 year
- -5.97%
News
defenseworld.net Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Now Rated “Moderate Buy” by Wall Street Analysts Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight ratings firms that are currently covering the firm, MarketBeat.com…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In Q4 Healthcare stocks Alnylam, Madrigal and Corcept appear oversold, with RSI near or below 30, offering potential opportunities for investors.
benzinga.com Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $173 Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $165 to $173.
benzinga.com Corcept Therapeutics Q3 2026 Earnings Call Transcript Corcept Therapeutics (NASDAQ:CORT) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Corcept Therapeutics Affirms FY2026 Sales Guidance of $1.100B-$1.200B vs $1.146B Est Corcept Therapeutics (NASDAQ:CORT) affirms FY2026 sales outlook from $1.100 billion-$1.200 billion to $1.100 billion-$1.200 billion vs $1.146 billion estimate.
benzinga.com Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study Corcept Therapeutics reported positive Phase 2 BELLA trial data for Lifyorli and chemotherapy in platinum-resistant ovarian cancer patients.
benzinga.com Corcept Therapeutics Announces Results From Part A Of Its Phase 2 BELLA Trial Of Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab In Patients With Ovarian Cancer; Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab Demonstrated Clinically Meaningful Progression-Free Survival, Objective Response Rate And Overall Survival Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic…
benzinga.com Oil Tops $100 on Iran Fears, Energy ETF XLE Hits New Record: Stock Market Today WTI crude rose above $100 on fears of renewed U.S. strikes on Iran, lifting XLE to a record while staples, telecoms and the Dow slipped at midday Friday.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $165 price target.
benzinga.com Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years Corcept Therapeutics (NASDAQ:CORT) has outperformed the market over the past 10 years by 20.4% on an annualized basis producing an average annual return of 33.86%. Currently, Corcept Therapeutics has…- benzinga.com Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165 Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $88 to $165.
benzinga.com Stock Market Today: Microsoft Ignites Chip Rebound as SanDisk Jumps 24% Microsoft's 43% cloud growth revived the AI trade and lifted chipmakers, but Meta's guidance miss and a 19-year high in 30-year yields capped the rebound.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session. GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap…- benzinga.com Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161 Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $150 to $161.
benzinga.com Lam Research, Xerox, FormFactor, Microsoft And Other Big Stocks Moving Higher On Thursday Dow Jones index gained 300 points, Lam Research Corp rose 20.1% after reporting strong financial results. Xerox, Columbus McKinnon, and other stocks recorded gains.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session. GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding…- benzinga.com HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $95 to $165.
- benzinga.com Why Microsoft Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket Microsoft (NASDAQ: MSFT) reported strong Q4 results, beating revenue and earnings estimates. Shares jumped 7.8% in pre-market trading.
benzinga.com Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know Corcept Therapeutics shares soared 21.95% after hours as strong quarterly results and raised guidance boosted investor confidence.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market session. Onconetix (NASDAQ:ONCO) shares moved upwards by 27.46% to $0.96. The company's market cap stands at…- benzinga.com Corcept Therapeutics Raises FY2026 Sales Guidance from $950.000M-$1.050B to $1.100B-$1.200B vs $1.008B Est Corcept Therapeutics (NASDAQ:CORT) raises FY2026 sales outlook from $950.000 million-$1.050 billion to $1.100 billion-$1.200 billion vs $1.008 billion estimate.
- benzinga.com Corcept Therapeutics Q2 EPS $0.36 Beats $(0.00) Estimate, Sales $256.147M Beat $219.988M Estimate Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $(0.00) by Infinity percent. This is a 24.14 percent increase over…
benzinga.com Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150 Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $135 to $150.
benzinga.com This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings page.
benzinga.com Wolfe Research Downgrades Corcept Therapeutics to Underperform, Announces $50 Price Target Wolfe Research analyst Kalpit Patel downgrades Corcept Therapeutics (NASDAQ:CORT) from Peer Perform to Underperform and announces $50 price target.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Corcept Therapeutics Refiles Its New Drug Application With Additional Analyses Of Data To FDA For Relacorilant To Treat Cushing's Syndrome Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic…
- benzinga.com 7 Health Care Stocks With Whale Alerts In Today's Session
- benzinga.com Reported Saturday, CATALYST Trial Data Show Korlym Reduces HbA1c By 1.3% And Body Weight By 5.1 Kg In Hypercortisolism Patients With Difficult-To-Control Diabetes New data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86th Scientific SessionsIn the CATALYST trial, patients with hypercortisolism treated with Korlym…
benzinga.com Corcept Therapeutics Discloses Amended Complaint Filed By Former Employee, Will Defend Itself Against Claims On May 19, 2026, Corcept Therapeutics Incorporated (the "Company") learned that the United States Department of Justice (the "DOJ") had filed a Notice of Election to Decline Intervention (the…- benzinga.com Corcept Therapeutics Announces New Overall Survival Data From Its Pivotal Phase 3 ROSELLA Trial Of Lifyorli Plus Nab-Paclitaxel In An Oral Presentation At The ASCO 2026; Patients Treated With Lifyorli Combined With Nab-Paclitaxel Experienced A 35 Percent Reduction In The Risk Of Death Compared To Patients Treated With Nab-paclitaxel Alone Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic…
- benzinga.com Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $135 Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $110 to $135.
benzinga.com Micron To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Thursday Top Wall Street analysts changed outlook on top names. See all analyst rating changes, including upgrades/downgrades, on Benzinga's page.
benzinga.com HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $95 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $75 to $95.- benzinga.com Corcept Therapeutics To Resubmit Its New Drug Application To FDA For Relacorilant To Treat Cushing's Syndrome Patients Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic…
- benzinga.com UBS Upgrades Corcept Therapeutics to Buy, Raises Price Target to $72 UBS analyst Ashwani Verma upgrades Corcept Therapeutics (NASDAQ:CORT) from Neutral to Buy and raises the price target from $44 to $72.
benzinga.com Packaging Corp Of America To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday Needham analyst Rick Patel maintained a Buy rating. Steven Madden shares closed at $47.27 on Friday. Top analysts change outlook on BTSG, CELC, ESS, CORT, PKG, PRU, RVTY, and SHOO. See how they rate…
benzinga.com Earnings Scheduled For April 30, 2026 
benzinga.com Amazon To Rally Around 49%? Here Are 10 Top Analyst Forecasts For Wednesday Top analysts change outlook for top names. Citigroup, Tigress Fin, Piper Sandler, Morgan Stanley, HC Wainwright, Susquehanna, Raymond James and Goldman Sachs adjust price targets for companies like…
benzinga.com AAR Foods Posts Upbeat Q3 Earnings, Joins Braze, Arm Holdings And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose, with the Dow Jones gaining 350 points on Wednesday. AAR Corp (NYSE: AIR) saw a 10.5% jump in shares after reporting strong earnings and raising its sales forecast.
benzinga.com Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics surges 29%. Oil down 2.1%, gold up 3.2%.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Stocks Rise, Oil Falls On Iran Ceasefire Hopes, ARM Surges 15% : What's Moving Markets Wednesday? U.S. stocks advanced Wednesday as oil prices fell on Iran diplomacy reports. Arm jumped 15%, while Treasury yields declined.
benzinga.com Brent Hits $110, Rate-Hike Fears Hammer Stocks And Gold: What's Moving Markets Friday? U.S. stocks fall to four-month lows as oil surges above $110, Treasury yields spike, and markets price a 50% chance of a Fed rate hike by October.- benzinga.com Earnings Scheduled For February 24, 2026
benzinga.com Stocks Fall, Oil Hits 7-Month High As Trump Weighs Iran Strike: What's Moving Markets Thursday? Stocks slipped Thursday as Trump comments on Iran lifted oil prices, boosting energy shares while financials and tech lagged midday Thursday.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Silver Breaks $101, Intel Stock Plunges 17%: What's Moving Markets Friday? Precious metals continued to dominate Wall Street headlines on Friday as silver surged through the $100-per-ounce threshold and traded around $101 per ounce by midday in New York, marking a…
benzinga.com Russell 2000 Extends Records, Meta Jumps 5%: What's Moving Markets Thursday? U.S. stocks surged midday Thursday as strong GDP data pushed the Russell 2000 to record highs and investors shrugged off tariff and geopolitical fears.